Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial

Kristian Reich*, Melinda Gooderham, Diamant Thaçi, Jeffrey J. Crowley, Caitriona Ryan, James G. Krueger, Tsen Fang Tsai, Mary Flack, Y. Gu, David A. Williams, Elizabeth H.Z. Thompson, C. Paul

*Corresponding author for this work
261   Link opens in a new tab Citations (Scopus)

Fingerprint

Dive into the research topics of 'Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science